ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Consultations, (antibiotic) prescriptions, and productivity losses of patients with community-acquired respiratory tract infection: country-specific findings from the PRUDENCE trial.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveRecent estimates of the cost-of-illness of community-acquired acute respiratory tract infections (CA-ARTI) are scarce. The current study aimed to estimate country-specific prescriptions, consultations, and productivity loss of patients with CA-ARTI in primary care.
methodsData were collected via baseline data and a patient diary alongside the PRUDENCE trial. This multinational clinical trial recruited patients visiting their general practitioner (GP) with CA-ARTI symptoms in ten countries. Data collected included the antibiotic class prescribed, consultations with healthcare providers, non-antibiotic medication prescribed for CA-ARTI, disease duration, and missed working hours. Hours of work missed due to the disease were multiplied by country-specific hourly labour cost to calculate productivity loss in terms of absenteeism.
resultsProportions of CA-ARTI patients receiving an antibiotic prescription ranged from 37.2% in Germany to 68.2% in Ireland. Broad-spectrum penicillin was the most frequently prescribed class in Belgium, Germany, and Ireland (> 40%), whereas macrolides were most frequently prescribed in Georgia, Greece, and Hungary (> 36%). On average, approximately 50% of patients reported having a follow-up consultation with their GP within two weeks of the initial appointment. On average, work missed due to CA-ARTI was 15.4 h among employed patients, resulting in an average productivity loss of €358 per patient, and ranged from €1260 in Germany to €24 in Georgia.
conclusionsAntibiotic prescriptions, healthcare use, and missed work hours for CA-ARTI were substantially different across participating countries. This study adds valuable information on the generalizability of health economic evidence regarding CA-ARTI between countries and indicates the relevance to collect country-specific data and perform country-specific health economic analyses.
Indexed as
Identifiers
42814231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.